Competition Issues in Pharmaceuticals: The Challenges Ahead
Thursday 22 June, etc.venues The Hatton, London EC1N 8HN, 9am - 6pm.
Hosted by the Centre for Competition Policy and the School of Economics at the University of East Anglia, this one day conference in London brought together academics and leaders from both industry and regulatory groups to identify and discuss the challenges facing the pharmaceutical industry today.
Consisting of five sessions, each with an academic presentation followed by a panel discussion, the conference attracted over 40 delegates from both academia and practitioner. Discussion was insightful with expert views and lively debate on the current competition problems and future issues this sector faces.
SESSION 1: 'Does reference pricing drive out generic competition in pharmaceutical markets? Evidence from a policy reform', Chiara Canta, NHH Norweigian School of Economics
SESSION 2: 'Secondary pharmaceutical patenting: A global perspective', Bhaven Sampat, Mailman School of Public Health, Columbia University
SESSION 3: 'Effect of SPCs and other exclusivity policies on consumer welfare and R&D investment behaviour', Margaret Kyle, MINES Paris Tech (presentation not available)
SESSION 4: 'Role of authorized generics in enabling pay for delay deals', Farasat Bokhari, Centre for Competition Policy & School of Economics, University of East Anglia
SESSION 5: 'Impediments to competition in US pharmaceutical industry', Fiona Scott Morton, Yale School of Management
Panellists include Gregory Asciolla, Partner at Labton Sucharow; Paul Csiszar, DG Comp; Tomaso Duso, DIW Berlin and DICE; The Rt Hon. Sir Robin Jacob, University College London; Susan Jones, Novartis International; Kai-Uwe Kühn, Centre for Competition Policy, University of East Anglia; Carmine Ornaghi, Southampton University; Pierre Regibeau, Charles River Associates; Pedro Caro de Sousa, OECD; Caroline Teyssié, Autorité de la concurrence; Mike Walker, Competition and Markets Authority.